UNSPSC 51433001: Olmidine

This classification denotes an antihypertensive agent with the molecular formula C9H10N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0T3B934Y1M, chemically known as 3,4-(methylenedioxy)mandelamidine but generally known as olmidine, which bears US NIH Compound Identifier 31491. European Medicines Agency schedules Olmidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09430MIG. The term OLMIDINE is an International Non-Proprietary Name.

UNSPSC 51433001 Olmidine is a Commodity code covering emergency and hospital medications supplied to state and local public-sector healthcare providers, particularly fire rescue services and state pharmacy benefit programs. State and local governments under this code procure specific injectable medications in bulk for advanced life support protocols, generic pharmaceuticals for multi-state cooperative purchasing agreements, and direct-to-manufacturer prescription fulfillment capabilities. Recent solicitations show fire rescue departments, state health agencies, and cooperative purchasing alliances as the primary issuing bodies. The scope spans sealed-bid procurements for standardized medication line items with strict expiration and delivery requirements, cooperative multi-state contracts for generic and over-the-counter pharmaceuticals through authorized wholesalers, and exploratory requests for information on direct contracting models that bypass traditional pharmacy benefit manager and group purchasing organization channels. Vendors must comply with FDA requirements, current Good Manufacturing Practices, Drug Supply Chain Security Act certification, OSHA safety documentation standards, and federal accessibility requirements for digital submissions.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (IFB 26P00188) for Tampa Fire Rescue in Hillsborough County with a due date of April 8, 2026 and estimated contract value of $40,000, requiring 370 units of Labetalol, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem with nine-month minimum expiration dates and ten-day delivery windows; the solicitation includes a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products due March 26, 2026, requiring NDC-specific pricing through three authorized wholesalers with contract effectiveness July 1, 2026 and a two-year term with optional extensions. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in late March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling potential future procurements for direct contracting models outside traditional PBM and GPO channels.